Multi-Atlas and Whole Body Radiomics Approaches for Image-Guided Treatment of Gynecologic Cancers

  • STATUS
    Recruiting
  • End date
    Feb 29, 2024
  • participants needed
    450
  • sponsor
    University of California, San Diego
Updated on 15 May 2022

Summary

  1. To compare acute toxicity and chemotherapy delivery for atlas-based IG-IMRT vs. PET/CT-based IG-IMRT vs. conventional RT, and assess the impact of treatment on changes in hematopoietic compensatory response.
  2. To develop and validate machine learning and radiomics techniques for dose accumulation, automated treatment planning, and prediction of treatment response.

Description

This is a grant to conduct correlative science associated with an ongoing NCI-sponsored multi-center cooperative group phase 3 trial (NRG-GY006; NCT02466971). Specifically, this R01 grant pertains to Aims 1.3.7 and 1.3.8 of that trial protocol. The primary objective of the NRG-GY006 is to test the hypothesis that the addition of triapine to standard chemoradiation with concurrent cisplatin can improve overall survival relative to the standard of care. Patients are randomized 1:1 between the experimental (i.e., triapine) and control (i.e., standard of care) arms. The present R01 grant seeks to investigate the effect of image-guided intensity modulated radiation therapy (IG-IMRT) relative to conventional RT on normal tissue toxicity and hematopoietic compensatory response. The investigators will compare 3 methods of delivering external beam radiation therapy: conventional 3D conformal radiotherapy (3DRT), positron emission tomography (PET)-based IG-IMRT, and atlas-based IG-IMRT. Patients are not randomized between the 3 types of radiation; rather, sites treat using 3DRT as a default, and are required to undergo additional credentialing for IG-IMRT. Once credentialed for IG-IMRT, sites are allowed only to treat with IG-IMRT in order to mitigate selection bias. Patients treated on the trial using IG-IMRT prior to 5/13/2019 (demarcating the conversion from phase 2 to phase 3) were treated with PET-based IG-IMRT. Patients treated on the trial using IG-IMRT after 5/13/2019 are treated with atlas-based IG-IMRT. Thus, there are potentially 6 groups to compare (2 chemotherapy arms and 3 RT modalities).

The specific aims of the grant are as follows:

Aim 1A: To test the hypothesis that multi-atlas-based IGRT reduces acute hematologic toxicity and improves chemotherapy delivery compared to conventional RT Aim 1B: To test the hypothesis that multi-atlas-based IGRT results in comparable acute hematologic toxicity and chemotherapy delivery compared to PET-based IGRT Aim 2A: To test the hypothesis that triapine reduces extra-pelvic compensatory hematopoiesis relative to therapy with cisplatin only Aim 2B: To test the hypothesis that IGRT (multi-atlas-based or PET-based) increases pelvic compensatory hematopoiesis relative to conventional radiotherapy Aim 3: To develop and validate a radiomics model for gynecologic cancer treatment outcomes that incorporates whole body imaging biomarkers of the inflammatory state and correlates with the effectiveness of triapine.

Details
Condition Gynecologic Cancer
Clinical Study IdentifierNCT05358600
SponsorUniversity of California, San Diego
Last Modified on15 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects enrolled to the GY006 clinical trial

Exclusion Criteria

Anyone not previously enrolled to the GY006 clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note